ABSTRACT In the United States, turkey production contributes approximately $14.4 billion to the US economy; however, the number of reagents specifically developed to study the immune system of this economically important species is limited. To compensate for this, laboratories focused on the turkey system have each empirically tested various chicken-specific reagents for cross-reactivity with turkeys. The result is a patchwork of reports using different genetic lines and different ages, and in many cases, leading to inconsistent conclusions about the cross-reactivity of the reagents tested. In the current study, we investigated a large panel of commercially available monoclonal antibodies specific for chicken leukocyte markers for their ability to specifically recognize the turkey homolog of their respective ligand using 2 different genetic lines of commercial turkeys. The results of these studies identify 8 chicken-specific monoclonal antibodies (F21-21, F21-2, CT4, EP96, 3-298, AV7, c264, and AV6) as demonstrating strong evidence for cross-reactivity with turkey peripheral blood mononuclear cells from both commercial lines, 3 of which (F21-2, EP96, and c264), to our knowledge, have not previously been reported. In addition, characterization of the anti-CD8α monoclonal antibody 3-298 provides evidence that turkeys, like chickens, have a relatively high percentage of CD4CD8 double-positive T-cells in circulation and have at least 5 alleles of the CD8α gene. Collectively, the results from these experiments strengthen our understanding of the turkey immune system, its relative level of conservation with the chicken system, and adds to the list of reagents that can be reliably used to assess immune responses in commercial turkeys.
INTRODUCTION

Annual consumption of turkey meat in the United
States is estimated at 7.7 kg/person, and turkey production contributes approximately $14.4 billion to the US economy (NTF, 2010) . In spite of the size and importance of the turkey industry, our understanding of the turkey immune system is limited relative to other species and is based largely on our understanding of chicken immunity (Schultz and Magor, 2008) . This affects our ability to develop vaccines and therapies specific to disease challenges facing the turkey industry.
Although several laboratories are focused on studying the turkey immune system and turkey diseases, they are far less numerous than those focused on understanding the chicken immune system. As a result, the development of reagents for turkeys has been slow and largely dependent on the identification of chicken-specific tools that cross-react. This has resulted in a patchwork of tools for the turkey system with significant gaps in reagents for fully identifying and characterizing turkey immune cells.
Numerous studies have investigated the ability of antichicken leukocyte monoclonal antibodies (mAb) to recognize turkey cells (Table 1) ; however, the results from these studies are often difficult to compare because the ability to cross-react and the percentage of cells recognized by a given mAb has varied among reports (Skjødt et al., 1986; Suresh et al., 1993; Jeurissen and Janse, 1998; Li et al., 1999; Qureshi et al., 2000; Lawson et al., 2001) . These inconsistencies make it difficult to select a panel of mAb for use in routine studies of the turkey immune system. This has a greater effect on studies using commercial turkeys where genetic variability within a flock may be more variable than within research lines.
The current study was designed to examine a large panel of commercially available chicken-specific mAb for cross-reactivity using 2 of the most commonly used commercial lines of turkeys.
MATERIALS AND METHODS
Birds
Four-to 6-wk-old broiler-type chickens were obtained from the North Carolina State University research flock and age-matched turkeys (line H or N) were obtained from a commercial hatchery (Goldsboro Milling, Goldsboro, NC). All animals were housed in temperaturecontrolled cages with free access to food and water and were treated in accordance with North Carolina State University approved IACUC guidelines.
Isolation of Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells (PBMC) were isolated from broiler-type chickens and 2 commercial lines of turkeys between 4 and 6 wk of age. Briefly, approximately 4 mL of blood was collected from each of 4 birds of each host-type using heparinized syringes. The PBMC were separated from the red blood cells using a density gradient (Ficoll 1077, Atlanta Biologicals, Law- Chan et al., 1988; Coltey et al., 1989; Char et al., 1990; Suresh et al., 1993; Li et al., 1999 Chan et al., 1988; Coltey et al., 1989; Char et al., 1990; Suresh et al., 1993; Tregaskes et al., 1995; Li et al., 1999 3-298 CD8α Cytotoxic T cells ++ + Luhtala et al., 1997a; Li et al., 1999; Qureshi et al., 2000; Lawson et al., 2001 EP72 CD8α Cytotoxic T cells − NR Chan et al., 1988; Tregaskes et al., 1995 EP42 CD8β Cytotoxic T cells − + Chan et al., 1988; Paramithiotis et al., 1991; Tregaskes et al., 1995; Li et al., 1999 Chen et al., 1984; Coltey et al., 1989; Char et al., 1990; Suresh et al., 1993; Jeurissen and Janse, 1998 TCR1 4 γδTCR γδT cells − − Sowder et al., 1988; Coltey et al., 1989; Char et al., 1990; Jeurissen and Janse, 1998 TCR2 4 αβ 1 TCR Subpopulation of αβT cells Chen et al., 1984; Cihak et al., 1988; Coltey et al., 1989; Char et al., 1990; Lawson et al., 2001 TCR3 4 αβ 2 TCR Subpopulation of αβT cells − − Coltey et al., 1989; Char et al., 1990 2-191 4 CD5 Thymocytes, T cells, subsets of B cells − NR Koskinen et al., 1998 Kit2C75 4 c-kit Oncogenic cells − NR Blume-Jensen et al., 1991; Sasaki et al., 1993; Iemura, et al., 1994; Kinashi and Springer, 1994; Yee et al., 1994; Vainio et al., 1996; Lampisuo, et al., 1998; Katevuo, et al., 1999; Lampisuo et al., 1999; Schulte et al., 2002 CT-1 4 Common thymocyte antigen Thymocytes − NR Chen et al., 1984; Houssaint et al., 1985; Kong et al., 1998; Katevuo et al., 1999 renceville, GA) as described previously (Qureshi et al., 2000) . The interface was collected and the cells washed twice with PBS (pH 7.5) + 2% BSA (Fisher Scientific, Pittsburgh, PA). The cells were counted and viable cells determined using trypan blue exclusion. Each sample was adjusted to give a viable cell concentration of 10 6 cells/mL, and equal numbers of cells from each animal were pooled (within host type). A minimum of 5 independent experiments were conducted for each host type.
Flow Cytometry
Pooled cells (10 6 ), isolated as described above, were centrifuged for 10 min at 250 × g at 10°C, supernatants decanted, and cells vortexed briefly. For single-parameter analysis, PBMC were then incubated for 1 h on ice with 0.5 μg of fluorescein isothiocyanate-conjugated mAb (Table 1) . For 2-color analysis, PBMC were incubated on ice for 1 h with 0.5 μg of CT4 (fluorescein isothiocyanate-labeled) mAb, washed, followed by a 1 h incubation on ice with 0.5 μg of 3-298 labeled with R-phycoerythrin mAb. Replicate cells were directly stained with 0.5 μg of a conjugated isotype control (Southern Biotech, Birmingham, AL) and used to determine background fluorescence. Cells were washed twice with PBS + 2% BSA, resuspended in 200 μL of PBS + 2% BSA, and then analyzed by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA) at the NCSU Flow Cytometry and Cell Sorting Laboratory (North Carolina State University, Raleigh, NC). Data were analyzed by gating on live cells and using Win-MDI 2.9 software (Joseph Trotter, Scripps Research Institute, La Jolla, CA). The background population was defined by setting the marker to approximately 3% of the isotype control for each PBMC population.
The average percentage of cells identified by each mAb were compared with the average positive percentage of the isotype control (background) using a paired t-test. The mAb found to recognize a statistically greater number of cells (P ≤ 0.05) than the isotype control were considered presumptive positive for cross-reactivity. Paired t-tests (P ≤ 0.05) were also used to compare the difference in cells recognized between chicken and turkey PBMC, between genetic lines of turkeys, and between mAb specific for the same surface antigen.
Turkey CD8α Sequence Analysis
Total RNA was isolated from line H and line N tissues using Trizol (Life Technologies, Carlsbad, CA). The RNA was converted to cDNA using oligo-dT primers and Smart MMLV reverse transcriptase (Clontech, Mountain View, CA). Then, CD8α was amplified using GoTaq Green Master Mix (Promega, Madison, WI) 5′-TATTTCCGGTGAATTATGGCCGGGTCTCCT-GCACTGCTC-3′ forward primer and 5′-TAGTC TCGAGGAATTCTCATATGTCTGGGGGTGGCA-CACT-3′ reverse primer (gene-specific regions underlined). The resulting amplicons were confirmed based on size following electrophoresis through a 1% agarose gel and visualized using ethidium bromide. Then, they were excised from the gel, purified, and sequenced (GeneWiz, South Plainfield, NJ). The resulting DNA sequences were then analyzed using Vector NTI Advance 10.0.1 (Life Technologies). Consensus nucleotide sequences were determined based on 4 replicate sequencing reactions for each RT-PCR product, and chromatogram files were analyzed to determine putative nucleotide positions with allelic differences. The predicted amino acid sequence was determined for each of the consensus nucleotide files and were aligned using ClustalX (http://www.clustal.org/clustal2/) with chicken CD8α (AY528647-51, EU477525, NM205235, Z22726, and AY519197) and turkey CD8α (AM884251 and XM003206019). The turkey CD8α sequences determined as part of this study have been assigned accession numbers JN698886-8.
Expression of Chicken and Turkey CD8α
Turkey (line N) and chicken CD8α were amplified from cDNA libraries using Phusion DNA polymerase (New England Biolabs, Ipswich, MA), turkey CD8α forward and reverse primers (specified above) or chicken CD8α forward and reverse primers (5′-TATTTCCGGT-GAATTCATGGGCCAGGTCTCCTGCACTGCTC-3′ and 5′-TAGTCTCGAGGAATTCTCATATGTGTC-GGGTTGGCACACA-3′, respectively, with gene-specific regions underlined), and cloned into an EcoRI digested pLVX-ZsGreen1 vector using the In-Fusion cloning system (Clontech, Mountain View, CA). The resulting clones were then verified by sequencing and used to transduce 293T cells following the manufacterer's instructions (Clontech). The resulting recombinant 293T cells (293T/chCD8α and 293T/tkCD8α) were then analyzed by flow cytometry for expression of ZsGreen1 and reactivity with mAb CT8 and 3-298. For this, 1.5 × 10 6 cells were incubated for 1 h at 4°C with 4 ng of CT8, 3-298, or isotype control mAb. Cells were then washed twice with PBS + 2% BSA and then incubated for 1 h at 4°C with 4 ng of goat antimouse IgG conjugated to Alexa Fluor 647 (Life Technologies). Cells were washed 3 times with PBS + 2% BSA, resuspended in 400 μL, and analyzed by flow cytometry (CyAn ADP, Beckman Coulter, Brea, CA) at the UNC flow cytometry core facility (University of North Carolina-Chapel Hill).
Statistical Analysis
Data were reported as mean ± SD. All data were analyzed by using a Student's t-test for differences. P < 0.05 was considered significant.
RESULTS AND DISCUSSION
Candidate AntiChicken mAb for Detection of Turkey Immune Cells
Twenty-three mouse antichicken mAb (Table 1) were initially screened for the ability to bind to turkey PBMC from lines H and N. This preliminary analysis identified 16 mAb of the 22 mAb that bound to more cells than the isotype control (data not shown). These 16 mAb were selected for subsequent analysis and were examined for their ability to recognize similar percentages of turkey PBMC as chicken PBMC. The average percentage of cells recognized by each mAb was determined ( Figure 1A) , and any one mAb was considered a presumptive positive for cross-reactivity with turkey PBMC if the percentage of positive cells was statistically different from the background population (isotype control). This analysis demonstrated 14 of the 16 mAb specifically bound to chicken PBMC ( Figure  1A ). Analysis of the turkey PBMC data demonstrated that 12 out of the 16 mAb bound to PBMC from line H, and 8 out of 16 mAb bound to PBMC from line N ( Figure 1A ).
Comparison of Fluorescent Profiles Among PBMC Populations
Analysis of the average percentage of positive cells demonstrated 4 mAb (CT8, EP42, 21-1A4, and CIa) bound to significantly more cells than the isotype control in line H but not in line N ( Figure 1A) ; however, the average number of cells recognized were not significantly different between lines H and N (data not shown). To begin to understand the significance of these results, the fluorescent profile of each mAb was compared among the different PBMC populations ( Figure 1A) . Analysis of the chicken PBMC histograms demonstrates discrete cell populations with fluorescent intensities of 1 to 2 decades higher than the isotype control population for each mAb, except 21-1A4 and 5-11G2, which were not significantly different from the isotype control ( Figure  1A ). The size and fluorescent intensity of this population varied among the mAb based on the distribution of the specific markers and level of surface expression of its corresponding antigen ( Figure 1A ). Comparatively, only half (8 out of 16) of the turkey PBMC (CT4, EP96, 3-298, F21-21, F21-2, c264, AV7, and AV6) demonstrated populations with fluorescent intensity of 1 to 2 decades higher than the isotype control ( Figure  1A ). The fluorescence profile for each of these mAb was similar between lines H and N ( Figure 1A ). Of the remaining 8 mAb (CT8, EP72, EP42, AV20, 21-1A4, 5-11G2, CIa, and LT40), 3 (EP72, AV20, and 5-11G2) were found to not be statistically different (α = 0.05 or 0.1) from the isotype control for either line H or N ( Figure 1A ), and therefore, were not examined further.
Single-parameter histograms were produced for line H, line N, and chicken PBMC for CT8, EP72, 21-1A4, CIa, and LT40 and were compared with the isotype control and on3 mAb (EP96) that demonstrated similar fluorescent profiles for all 3 PBMC populations ( Figure  1B) . Analysis of the fluorescent profile of CT8, EP42, 21-1A4, CIa, and LT40 demonstrated an increase in the mean fluorescent intensity (MFI) of the background population that then crossed into the marker, increasing the number of turkey PBMC within the maker ( Figure 1B) . The increase in MFI was not statistically significant (data not shown), but the increased MFI did appear to lead to increased numbers of percent-positive events that were statistically significant ( Figure 1A and B). The increased fluorescence of the background population (marker R1, Figure 1B ) was observed for all mAb when using line H PBMC, except EP96 that demonstrates 2 distinct cell populations. Similarly, line N PBMC were found to have an increased MFI for 4 of the 6 mAb, the exceptions being EP96 and EP42, which did not detect more cells than the control in line N ( Figure 1A) . Conversely, chicken PBMC only demonstrated this increased MFI in the background population for 2 mAb: 21-1A4, which did not detect more cells than the control ( Figure 1A) , and LT40, which detects all cells. Collectively, these results may explain why line H had a higher number of mAb that were significantly different from its corresponding isotype control than line N.
These results also highlight the need for rigorous comparisons of staining properties of a given mAb against chicken cells and turkey (or other species) cells. Given the limited numbers of reagents available it is tempting to conclude that any mAb that binds more cells than the isotype control is cross-reacting. In the current study, the mAb produced by clone LT40 was not found to recognize turkey cells (α = 0.05); however, using a different statistical cutoff, one could have determined LT40 did bind to cells from line H (P = 0.0575) or line N (P = 0.103). In fact, the major reason LT40 was found to not be significantly different than the isotype control in this study was due to the level of variation in the percentage of LT40 positive cells across the replicate experiments (line H 14.8 ± 5.9 and line N 11.5 ± 8.5; Figure 1A ). Given the fact that clone LT40 is specific for the CD45 antigen found on all leukocytes (Paramithiotis et al., 1991) , it is relatively easy to conclude that LT40 is not recognizing the turkey homolog of CD45. This conclusion, however, would be more difficult if the same results were observed with a mAb against a marker found on a specific subset of leukocytes, especially one whose numbers might vary dramatically depending on age, stress, or disease status. Under these conditions, comparison of the overall fluorescent profile, and not mere reliance on the numbers of cells identified, is critical.
mAb Against the Same Antigen Recognize Different Percentages of PBMC
Among the panel of mAb analyzed in this study, there were 2 directed against the surface marker CD4 (CT4 and EP96), and 3 mAb were directed against CD8α (CT8, 3-298, and EP72). Comparison of the percentages of cells recognized by these different reagents demonstrated no significant difference in the numbers of CD4 + cells identified by CT4 and EP96 in the chickens or turkey lines H or N PBMC (P = 0.151, P = 0.134, and P = 0.091, respectively); however, there were differences in the numbers of chicken PBMC identified by the anti-chCD8α mAb. Comparison of the numbers of chicken PBMC recognized by the various anti-CD8α mAb demonstrated that CT8 and EP72 recognize the same percentage of chicken PBMC (P = 0.534); however, 3-298 recognized significantly more chicken PBMC than CT8 (P = 0.023) and EP72 (P = 0.038). The reason for these differences is currently unknown. The only study, to our knowledge, to use 3-298 in the identification of CD8 + T-cells in chickens describes the inheritability of CD4 + CD8 + peripheral T-cell populations in some genetic lines of chickens (Luhtala et al., 1997a) .
Multiple Alleles of CD8α
One possible explanation for the difference in the number of chicken and turkey PBMC recognized by the different anti-chCD8α mAb is polymorphims within the CD8α gene. Several reports have suggested that polymorphisms in the CD8α gene in chickens and turkeys explains the differences in the number of CD8 + cells identified by different CD8α-specific mAb (Luhtala et al., 1997b; Li et al., 1999) . More recent studies have demonstrated that as many as 6 alleles of CD8α exist in chickens (Hu et al., 2007) , and although allelic differences in turkey CD8α has been inferred from differences in mAb reactivity (Li et al., 1999; Powell et al., 2008) , there are no previous reports, to our knowledge, of DNA sequence evidence for CD8α polymorphisms in turkeys. To determine if differences in the CD8α alleles expressed by the turkey lines H and N might explain the different number of CD8α + cells identified by the different mAb, the full coding sequence of the turkey CD8α gene was amplified, sequenced, and the consensus nucleotide sequence determined for both lines H and N CD8α. The predicted amino acid sequences were then aligned with previously reported CD8α sequences from both chickens and turkeys. This analysis demonstrated the presence of 5 CD8α alleles among the 9 chicken sequences, representing 7 breeds of chickens (Figure 2A) . Similarly, analysis of the turkey sequences identified at least 4 alleles of CD8α (Figure 2A ). Previous characterizations of polymorphisms of chicken CD8α identified 13 codon positions with nonsynonymous changes, the majority of which were found to be in the major histocompatibility complex class-I binding complementary determining region 1, 2, or 3, residues involved in binding to the α3 region of the major histocompatibility complex class-I protein (Luhtala et al., 1997b; Hu et al., 2007) . Analysis of the nucleotide sequence demonstrated 11 codon positions contained polymorphisms, 8 of which result in changes in the amino acid sequence ( Figure 2B ). Interestingly, none of the amino acid changes found among the turkey CD8α gene were found within the putative complementary determining regions 1, 2, or 3 of the protein (Figure 2 ). Further comparison of the chicken and turkey CD8α sequences demonstrated the turkey homolog contains 2 additional codons (amino acids 143 and 160; Figure 2A) ; amino acid 143 was not found in one of the previously reported turkey CD8α sequences (Figure 2 ). The significance of this insertion/deletion among different turkey alleles is not known. Collectively, analysis of the variation in the turkey CD8α sequence demonstrates potential differences in allelic frequencies among genetic lines, which could explain differences in reactivity to various mAb; however, more extensive analysis of the numbers of CD8α alleles and their distribution in different turkey lines is needed to establish correlations.
3-298 CT4 Double-Positive Turkey PBMC
Of the different CD8α-specific mAb, 3-298 is one of the most commonly used to identify turkey CD8 + cells, and in this study, 3-298 was the only CD8-specific mAb that demonstrated cross-reactivity with both lines H and N (Figure 1 ). This specific mAb, however, has been reported to recognize a novel population of CD4 + CD8α + T-cells in some inbred lines of chickens (Luhtala et al., 1997a) as well as turkeys (Li et al., 2000) . To determine if mAb 3-298 identifies cells that are CD8α + or populations of CD4 + CD8 + turkey cells, PBMC were isolated from line N and analyzed by flow cytometry using both 3-298 and CT4 (anti-CD4). Analysis of the bivariate histogram (Figure 3) demonstrates that 3% of the cells are 3-298 + , 2% are CT4 + , and 14% are positive for both markers.
Although immunological dogma suggests CD4 CD8 double-positive cells are only found in the thymus during T-cell maturation, several reports in mammals and poultry suggest some species have circulating mature double-positive T-cells (Zuckermann, 1999) . The function of these cells is still unknown; however, reports from various species consistently describe these cells as being CD4 + T-helper cells that have developed the coexpression of CD8α following repeated exposures to antigen (Erf et al., 1998; Zuckermann, 1999) . Functional studies of these double-positive T-cells in pigs suggest they have an increased production of interferon-γ following antigen-specific stimulation (Zuckermann and Husmann, 1996) . Phenotypically, these double-positive cells are typically CD8α dim (Breed et al., 1996; Erf et al., 1998; Zuckermann, 1999) . The results observed with CT4 and 3-298 in the present data (Figure 3 ) also suggest there are 2 populations of 3-298 + cells in these samples, a 3-298 bright population seen in the upperleft quadrant and a 3-298 dim population just above the marker separating the upper-right quadrant from the lower right (Figure 3 ). This suggests that the 3-298 bright population is likely CD8 + cytotoxic T-cells, whereas the 3-298 dim population are CD4 + helper Tcells co-expressing CD8α gene. These results confirm previous studies by Li et al. (2000) and provide additional evidence that turkeys, like chickens, have high numbers of CD4CD8α double-positive cells in circulation. It should be noted, however, that CD4CD8 dou- A) The predicted amino acid sequence of CD8α from 9 chickens and 5 turkeys were aligned using ClustalX. The consensus amino acid sequence is shown at the top of the alignment. Individual residues in common with the consensus are represented by a dash. Amino acids in bold denote a cystine residue conserved across species. ~ Denotes positions in the alignment with amino acid insertions. The CD8α signal peptide is highlighted by a dashed box. The transmembrane domain is highlighted by shaded boxes, and the polybasic residues of the cytoplamsic tail are denoted by +. The complementary determining 1, 2, and 3 regions of the CD8α protein, predicted to interact with the α3 region of the major histocompatibility complex-I molecule are denoted by the black line above the alignment. # Denotes amino acid positions in the turkey CD8α gene with putative allelic variants. B) Alignment of turkey CD8α codon positions identified as having nucleotide changes among the various sequences. The triplicate nucleotide sequence for each source is listed at the top of the figure and the resulting amino acid encoded below. Missing codons and amino acids are denoted by ___ and _ respectively. For any sequence where more than one codon was identified, the dominant codon, and resulting amino acid, is listed first. ble-positive populations described in chickens and other species are exclusively CD8α not CD8β (Luhtala et al., 1997a; Zuckermann, 1999) . The only reagent identified in this that was specific for turkey CD8 is specific for the α chain, this highlights the need for the development of antibodies specific for the turkey CD8β for use in studies of turkey cytotoxic T-cell responses.
It should also be noted that the CD8α dim and bright populations can also be observed in the chicken PBMC stained with 3-298 ( Figure 1A) . The CD8α dim population is not present, or not as pronounced, in the chicken PBMC populations when stained with CT8 or EP72. This difference likely contributes to the differences in the number of CD8 + cells each mAb recognized ( Figure  1A ) and may suggest mAb 3-298 binds to a region of the CD8α protein that is more accessible when in the αα homodimer (found on CD4 + CD8 + cells) as compared with the αβ heterodimer found on CD4 -CD8 + cells (Breed et al., 1996) . Additional studies are necessary to understand the mechanisms behind these differences.
mAb 3-298 Specifically Recognizes Turkey CD8α
Alternatively, mAb 3-298 was produced to recognize chicken CD8α, and chicken and turkey CD8α are only 86 to 87% similar (Figure 2) . It is possible that this mAb is specifically recognizing another closely related surface protein on turkey cells. To accurately interpret the biological significance of any data generated using mAb 3-298 across species, it is important to verify that the mAb is capable of specifically recognizing the turkey CD8α protein. To accomplish this, the coding region of both chicken CD8α and turkey CD8α (line N) were cloned into a bisitronic expression vector and transduced into 293T cells. These recombinant 293T cells (293T/chCD8α and 293T/tkCD8α) were then analyzed by flow cytometry for using mAb CT8 and 3-298 (Figure 4) . Transduced cells were identified by the expression of the reporter gene ZsGreen, and the ability of either mAb to recognize CD8α transgene was determined based on the number of CD8α + ZsGreen + cells identified. The results of these experiments demonstrated approximately 3% of 293T/chCD8α cells and 6% of the 293T/tkCD8α cells were transduced (Figure 4) . Within these 2 recombinant cell types, all of the chicken CD8α transduced cells were identified as CD8α + by both the CT8 as well as 3-298 mAb, whereas conversely, only mAb 3-298 recognized all 6% of the turkey CD8α transduced cells (Figure 4) . Interestingly, mAb CT8 appeared to recognize approximately half of the turkey CD8α transduced cells; the reason for this is presently unknown.
Cross-Reacting mAb
Based on the parameters used in this study and the tools currently available for the characterization of turkey PBMC, 8 mAb (F21-21, F21-2, CT4, EP96, 3-298, AV7, c264, and AV6) were identified as demonstrating strong evidence for cross-reactivity with PBMC from commercial lines H and N. These mAb each identified a greater number of cells than the corresponding isotype control, identified a similar number of turkey PBMC as chicken PBMC, and demonstrated fluorescent profiles in turkey PBMC similar to those observed with chicken PBMC (Figure 1 ). Of these 8 mAb, there were 3 (F21-2, EP96, and c264), to the best of our knowledge, for which cross-reactivity with turkeys has not been reported. The remaining 5 mAb have all previously been reported to recognize turkey cells (Skjødt et al., 1986; Suresh et al., 1993; Li et al., 1999; Lawson et al., 2001) .
Of the remaining mAb tested (Table 1) , there is no evidence, or at best weak evidence, for reliable cross-reactivity such that our laboratory would not use them in future studies of the turkey immune response. Several of these mAb have previously been reported to crossreact with turkey PBMC (CT8, EP42, and AV20). The differences in the results of the current study with previous ones may be a function of differences in the genetic lines used and underlines the inherent difficulty of using mAb across-species. Two of the mAb (LT40 and EP72) do not have reports of cross-reactivity, to the best of our knowledge, and were found to not crossreact with turkey PBMC in this study. It should be noted that the mAb that are reported to recognize ChB6 (AV20, 21-1A4, and 5-11G2) were among the mAb that demonstrated no evidence of cross-reactivity; however, in previous experiments using a research genetic line of turkeys, these mAb did demonstrate strong evidence for cross-reactivity (data not shown), which suggests studies using antichicken CD markers need to be empirically tested for each genetic line of turkeys until sufficient information about the conservation of each of these surface proteins between chickens and turkeys is understood and turkey-specific mAb are produced.
Conclusions
The current study examined a panel of chicken-specific mAb for cross-reactivity with PBMC isolated from 2 different commercial lines of turkeys to identify reagents that could reproducibly be used to phenotype turkey leukocytes. Although the cross-reactivity of several of these mAb has previously been reported, the current study represents the largest survey, to our knowledge, of different mAb and their reactivity against different genetic lines of turkeys. Collectively, the results of the current experiments identify 8 mAb that have strong evidence for cross-reactivity with PBMC from commercial turkeys from 2 different genetic lines. The majority of these mAb have all previously been reported to cross-react, suggesting these mAb reliably bind turkey cells independent of age, cell isolation method, and genetic line. In addition, these data demonstrate that turkeys, like chickens, have multiple CD8α alleles as well as have relatively high levels (compared with humans and mice) of CD4 + CD8α + cells in circulation, highlighting the need for species-specific reagents to ensure our ability to understand the immune response of commercial turkeys and develop more effective vaccines and therapies for this economically important species. 
